Supernus Pharmaceuticals

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$192,103
$165,453
$149,824
$174,159
Gross Profit
143,772
148,626
134,061
148,061
EBITDA
-36,596
33,499
17,787
45,227
EBIT
-57,954
12,141
-2,596
26,382
Net Income
-45,117
22,499
-11,827
15,328
Net Change In Cash
192,103
165,453
149,824
174,159
Free Cash Flow
-61,793
58,080
30,272
44,193
Cash
151,371
144,711
115,848
69,331
Basic Shares
56,552
56,643
55,864
56,464

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$661,817
$607,521
$667,238
$579,775
Gross Profit
583,911
523,742
580,017
504,714
EBITDA
178,284
90,043
153,356
129,193
EBIT
97,870
5,184
67,813
96,598
Net Income
73,865
1,316
60,711
53,424
Net Change In Cash
661,817
607,521
667,238
579,775
Cost of Revenue
-110,314
-85,206
Free Cash Flow
171,226
110,534
116,414
125,082
Cash
69,331
75,054
93,120
203,434
Basic Shares
55,959
55,506
61,679
54,356

Earnings Calls

QuarterEPS
2025-12-31
$0
2025-09-30
-$0.80
2025-06-30
$0.40
2025-03-31
$0.43